Biosketch Joan Seoane

Biosketch Joan Seoane
Joan Seoane
jseoane@vhio.net
Posición actual
  • Codirector del Programa de Investigación preclínica y Traslacional, VHIO, Barcelona, España.
  • Jefe del Grupo de Expresión Génica y Cáncer
  • Profesor investigador de ICREA, 2004
  • Miembro del Comité Científico Interno del VHIO
  • Profesor de la Universidad Autónoma de Barcelona
Honores y membresía
  • Fundador de Mosaic Biomedicals (2012). Primer compuesto MSC-1 en ensayo clínico de fase 2 (2021)
  • Secretario General de la Asociación Europea para la Investigación del Cáncer (EACR)
  • Miembro de la Academia Europea de Ciencias del Cáncer (EACS)
  • Miembro del Comité de Neuroncología del Hospital Universitario Vall d’Hebron
  • Miembro de la Junta Directiva de la Asociación Española contra el Cáncer (AECC)
  • Miembro del cuerpo docente de la Sociedad Europea de Oncología Médica (ESMO)
  • Miembro del Comité Científico de la Fundación Seve Ballesteros
Patentes
  • Título: Novel Use of Quinazolinone Compound for the Treatment of Cancer.
    Solicitud n./Patent N: 212063336.6.
    Con licencia de: F. Hoffmann-La Roche AG.
    Fecha de registro: November 4th, 2021
  • Título: Methods for Improving Response to Anti-LIF Antibody Treatment in Individuals with Cancer
    Solicitud n.º / patente n.º: Presentación de solicitud de patente PCT y no provisional para los EE. UU. hasta el 18 de junio de 2019
    Con licencia de Mosaic Biomedicals, S.L.U y otros.
    Fecha de registro: 18 de junio de 2018
  • Título: Combination of LIF Inhibitors and Platinum-based Antineoplastic Agents for Use in Treating Cancer
    Solicitud n.º / patente n.º: Presentación de solicitud de patente PCT y no provisional para los EE. UU. hasta el 18 de junio de 2019
    Con licencia de Mosaic Biomedicals, S.L.U y otros.
    Fecha de registro: 18 de junio de 2018
  • Título: Methods of Quantifying LIF and Uses Thereof
    Solicitud n.º / patente n.º: Presentación de solicitud de patente PCT y no provisional para los EE. UU. hasta el 18 de junio de 2019
    Con licencia de Mosaic Biomedicals, S.L.U y otros.
    Fecha de registro: 18 de junio de 2018
  • Título: Antibodies against LIF and dosage forms thereof.
    Solicitud n.º / patente n.º: Presentación de solicitud de patente PCT y no provisional para los EE. UU. hasta el 14 de mayo de 2019
    Con licencia de Mosaic Biomedicals, S.L.U y otros.
    Fecha de registro: 14 de mayo de 2018
  • Título: Combination Of Lif Inhibitors And Pd-1 Axis Inhibitors For Use In Treating Cancer.
    Solicitud n.º / patente n.º: 18382248.5-1111
    Con licencia de Mosaic Biomedicals, S.L.U y otros.
    Fecha de registro: 12 de abril de 2018
  • Título: Antibodies Against Lif And Uses Thereof
    Solicitud n.º / patente n.º: EP16382617.5
    Con licencia de Mosaic Biomedicals, S.L.
    Fecha de registro: 19 de diciembre de 2016
  • Título: Agents For The Treatment Of Diseases Associated With Undesired Cell Proliferation.
    Solicitud n.º / patente n.º: P12417EP00
    Con licencia de Mosaic Biomedicals, S.L.
    Fecha de registro:  27 de noviembre de 2015
  • Título: Antibody Recognizing Human Leukaemia Inhibitory Factor (Lif) And Use Of Anti-Lif Antibodies In The Treatment Of Diseases Associated With Unwanted Cell Proliferation.
    Solicitud n.º / patente n.º: EPA1038049.6
    Con licencia de Mosaic Biomedicals, S.L.
    Fecha de registro: 5 de abril de 2010
  • Título: Therapeutic Agents For The Treatment Of Diseases Associated With Undesired Cell Proliferation.
    Solicitud n.º / patente n.º:  ESA200900928
    Con licencia de Mosaic Biomedicals, S.L.
    Fecha de registro: 3 de abril de 2009
Formación académica
  • Licenciado en Ciencias Químicas por la Universidad de Barcelona, 1993
  • Doctor en Bioquímica y Biología Molecular por la Universidad de Barcelona, 1998
  • Becario de investigación, Memorial Sloan-Kettering Cancer Center, 1998
  • Investigador asociado, Memorial Sloan-Kettering Cancer Center, 2001
  • Profesor investigador de ICREA, 2004
Áreas de investigación
  • Estudio de los mecanismos moleculares implicados en tumores cerebrales
  • Estudio del microambiente tumoral
  • Estudio de la heterogeneidad intratumoral y de la evolución del tumor
  • Biopsias líquidas para el cáncer cerebral
  • Diseño de nuevos compuestos contra el cáncer
Premios y becas
  • Premio de investigación del Memorial Sloan-Kettering Cancer Center (2003)
  • Premio Josep M. Sala Trepat de la Sociedad Catalana de Biología (2004)
  • Premio EMBO para jóvenes investigadores (2007)
  • Premio Banc de Sabadell de Investigación Biomédica (2009)
  • Premio Beckman-Coulter de la Sociedad Española de Bioquímica y Biología Molecular (2009)
  • ERC, Consejo Europeo de Investigación (StG 2009, PoC 2012, PoC 2015)
  • Asociación para la Investigación Internacional del Cáncer (AICR) (2006)
  • Premio de investigación sobre el cáncer Dr. Josef Steiner (2013)
  • IV Premio Doctores Diz Pintado (2015)
  • Fundación Ramón Areces (2019)
  • Pfizer Foundation (2021)
Projects

 

Project Tittle: Biopsia Líquida para la caracterización y monitorización de la metástasis leptomeníngea.
Principal Investigator: Joan Seoane
Funding Agency: Fundación Contigo
Duración: 2023

Project Tittle: Generate a novel of patient-derived ex vivo tumor platform that recapitulates the native tumor microenvironment of cancer patients.
Principal Investigator: Joan Seoane
Funding Agency: JBID PROJECT ASTRAZENECA
Duration:2023-2026

Project Tittle: GNOT (Grup de Neuro-Oncologia Translacional).
Principal Investigator: Joan Seoane
Funding Agency: Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) Servei General de Recerca (SGR).
Duration:2023-2026

Project Title: Exploring the feasibility of predictive and pharmacodynamics biomarkers of immunotherapy in solid tumors (Immune-4ALL).
Principal Investigator: Joan Seoane
Funding Agency: ISCIII
Project reference: PMP22/00054
Duration: 2023-2026

Project Title: Estudio del microambiente inmunosupresor del tumor cerebral.
Principal Investigator: Joan Seoane
Funding Agency: ISCIII-FIS
Project reference: PI22/00130
Duration: 2023-2025

Project Title: Next generation cancer immunotherapy: targeting the tumour microenvironment.
Principal Investigator: Joan Seoane
Funding Agency: TRANSCAN-3
Duration: 2022-2025

Project Title: 2nd BBVA Foundation Comprehensive Program of Cancer Immunotherapy & Immunology.
Principal Investigator: Joan Seoane
Funding Agency: BBVA
Duration: 2022-2025

Project Title: Investigating the activity of a novel small molecule anticancer agent in PDX derived from MSI-H patients progressive to immunotherapies.
Principal Investigator: Joan Seoane
Funding Agency: ROCHE
Duration: 2022-2023

Project Title: Estudio del microambiente inmunosupresor del tumor cerebral
Project Reference: PI19/00318
Principal Investigator: Joan Seoane
Funding Agency: ISCIII-FIS
Duration: 2020-2022

 

Project Title: Study of the molecular mechanisms involved in primary (glioblastoma) and secondary (metastasis) brain tumors to identify novel therapeutic targets and anti-cancer agents, biomarkers to select treatments and novel non-invasive methods for molecular diagnosis.
Project Reference: GCTRA16015SEDA
Principal Investigator: Joan Seoane
Funding Agency: Fundación Científica de la AECC
Duration: 2017-2022

Project Title: Papel de LIF y TGFb en la regulación del sistema inmunológico en glioblastoma y metástasis cerebrales
Project Reference: CD18/00223
Principal Investigator: Joan Seoane
Funding Agency: Institute of Health Carlos III – Sara Borrell
Duration: 2019-2021

Project Title: Identification of novel immunotherapeutic targets in lung and melanoma brain metastases.
Project Reference: CIVP19A5943
Principal Investigator: Joan Seoane
Funding Agency: Ramon Areces Foundation.
Duration: 2019-2022

Project Title: Caracterización molecular mediante el estudio del ADN circulante en líquido cefalorraquídeo para la mejora del tratamiento del tumor cerebral 2019-2022
Project Reference: CIVP19A5943
Principal Investigator: Joan Seoane
Funding Agency: FERO Foundation
Duration: 2019-2022

Project Title: Impact of the brain tumor microenvironment on the response of brain malignancies to immunotherapies
Principal Investigator: Joan Seoane
Funding Agency: BBVA Foundation
Duration: 2018

A selection of recent news coverage

02/08/2022

08/03/2021

08/03/2021

04/03/2021

18/02/2021

27/10/2020

12/06/2019

19/01/2018

07/09/2017

16/03/2017  

03/02/2017 

03/02/2017

23/09/2016

29/04/2016

30/01/2016

05/02/2015

28/01/2015

06/11/2014

08/09/2014

11/10/2013

Most relevant scientific publications
  • Hallett R, Bonfill-Teixidor E, Iurlaro R, Arias A, Raman S, Bayliss PE, Egorova O, Neva-Alejo A, McGray AR, Lau E, Bosch A, Beilschmidt M, Maetzel D, Fransson J, Huber-Ruano I, Anido J, Julien JP, Giblin PA, Seoane J. Therapeutic targeting of LIF overcomes macrophage mediated immunosuppression of the local tumor microenvironment. Clin Cancer Res. Epub 2022 Nov 28:CCR-21-1888.
  • Iurlaro R, Waldhauer I, Planas-Rigol E, Bonfill-Teixidor E, Arias A, Nicolini V, Freimoser-Grundschober A, Cuartas I, Martínez-Moreno A, Martínez-Ricarte F, Cordero E, Cicuendez M, Casalino S, Guardia-Reyes X, Fahrni L, Pöschinger T, Steinhart V, Richard M, Briner S, Mueller J, Osl F, Sam J, Colombetti S, Bacac M, Klein C, Pineda E, Reyes-Figueroa L, Di Somma A, González J, Nuciforo P, Carles J, Vieito M, Tabernero J, Umaña P, Seoane J. A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma. Mol Cancer Ther. 2022 Oct 7;21(10):1499-1509.
  • Bonfill-Teixidor E, Iurlaro R, Handl C, Wichmann J, Arias A, Cuartas I, Emmenegger J, Romagnani A, Mangano L, Lorber T, Berrera M, Godfried Sie C, Köchl F, Eckmann J, Feddersen R, Kornacker M, Schnetzler G, Cicuendez M, Cordero E, Topczewski TE, Ferres-Pijoan A, González J, Martínez-Ricarte F, Muñoz-Couselo E, Tabernero J, Bischoff JR, Pettazzoni P, Seoane J. Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis. Cancer Res. 2022 Jul 18;82(14):2552-2564.
  • Borazanci E, Schram AM, Garralda E, Brana I, Vieito Villar M, Spreafico A, Oliva M, Lakhani NJ, Hoffman K, Hallett RM, Maetzel D, Hua F, Hilbert J, Giblin P, Anido J, Kelly A, Vickers PJ, Wasserman R, Seoane J, Siu LL, Hyman DM, Hoff DV, Tabernero J. Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors. ESMO Open. 2022 Aug;7(4):100530.
  • Raffaella Iurlaro, Inja Waldhauer, Ester Planas-Rigol, Ester Bonfill-Teixidor, Alexandra Arias, Valeria G. Nicolini, Anne Freimoser-Grundschober, Isabel Cuartas, Alba Martinez-Moreno, Francisco Martinez-Ricarte, Esteban Cordero, Marta Cicuendez, Simona Casalino, Xavier Guardia, Linda Fahrni, Thomas Poeschinger, Virginie Steinhart, Marine Richard, Stefanie Briner, Joerg PJ. Mueller, Franz Osl, Johannes Sam, Sara Colombetti, Marina Bacac, Christian Klein, Estela Pineda, Luis Reyes-Figueroa, Alberto Di Somma, Josep Gonzalez, Paolo G. Nuciforo, Joan Carles, María Vieito, Josep Tabernero, Pablo Umana, Joan Seoane; A novel EGFRvIII-T cell bispecific antibody for the treatment of glioblastoma. Mol Cancer Ther 2022; https://doi.org/10.1158/1535-7163.MCT-22-0201.
  • Seoane J, Escudero L. Cerebrospinal fluid liquid biopsies for medulloblastoma. Nature Reviews Clinical Oncology. 2022;19(2):73-74.
  • Escudero L , Martínez-Ricarte F, Seoane J. ctDNA-Based Liquid Biopsy of Cerebrospinal Fluid in Brain Cancer. Cancers. 2021; 13 (9):1989.
  • Rubio-Perez C, Planas-Rigol E, Trincado JL, Bonfill-Teixidor E, Arias A, Marchese D, Moutinho C, Serna G, Pedrosa L, Iurlaro R, Martínez-Ricarte F, Escudero L,  Cordero E, Cicuendez M, Ruiz S, Parra G, Nuciforo P, Gonzalez J, Pineda E, Sahuquillo J, Tabernero J, Heyn H, Seoane J. Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. Nature Communications. 2021; 12(1):1503.
  • Milena Cribiù F, Erra R, Pugni L, Rubio Perez C, Alonso L, Simonetti S, Croci GA, Serna G, Ronchi A, Pietrasanta C, Lunghi G, Fagnani AM, Pinana M, Matter M, Tzankov A, Terracciano L, Anton Pagarolas A, Ferrazzi E, Ferrero S, Iurlaro E, Seoane J*, Nuciforo P*. Severe SARS-CoV-2 placenta infection can impact neonatal outcome in the absence of vertical transmission. (*co-corresponding authors). Journal of Clinical Investigation. 2021;131(6):e145427.
  • Bobillo S, Crespo M, Escudero L, Mayor R, Raheja P, Carpio C, Rubio-Perez C, Tazón-Vega B, Palacio C, Carabia J, Jiménez I, Nieto JC, Montoro J, Martínez-Ricarte F, Castellví J, Simó M, Puigdefàbregas L, Abrisqueta P, Bosch F, Seoane J. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica. 2021; 106(2):513-521.
  • Escudero L, Martínez-Ricarte F, Seoane J. Cerebrospinal fluid circulating tumour DNA as a liquid biopsy for central nervous system malignancies. Curr Opin Neurol. 2020; 33(6):736-741.
  • Escudero L, Llort A, Arias A, Diaz-Navarro A, Martínez-Ricarte F, Rubio-Perez C, Mayor R, Caratú G, Martínez-Sáez E, Vázquez-Méndez É, Lesende-Rodríguez I, Hladun R, Gros L, Ramón y Cajal S, Poca M, Puente X, Sahuquillo J, Gallego S, Seoane J. Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma. Nature Communications. 2020; 11(1):5376.
  • Pascual-García M, Bonfill-Teixidor E, Planas-Rigol E, Rubio-Perez C, Iurlaro R, Arias A, Cuartas I, Sala-Hojman A, Escudero E, Martínez-Ricarte F, Huber-Ruano I, Nuciforo P, Pedrosa L, Marques C, Braña I, Garralda E, Vieito M, Squatrito M, Pineda E, Graus F, Espejo C, Sahuquillo J, Tabernero J, Seoane J. LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8 + T cell tumor-infiltration impairing anti-PD1 therapy. Nat Commun. 2019 Jun 11;10(1):2416.
  • Seoane J, De Mattos-Arruda L, Le Rhun E, Bardelli A, Weller M. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases. Ann Oncol. 2019 Feb 1;30(2):211-218.
  • Siravegna G, Mussolin B, Venesio T, Marsoni S, Seoane J, Dive C, Papadopoulos N, Kopetz S, Corcoran RB, Siu LL, Bardelli A. How liquid biopsies can change clinical practice in oncology. Ann Oncol. 2019 Oct 1;30(10):1580-1590.
  • De Mattos-Arruda L, Sammut SJ, Ross EM, Bashford-Rogers R, Greenstein E, Markus H, Morganella S, Teng Y, Maruvka Y, Pereira B, Rueda OM, Chin SF, Contente-Cuomo T, Mayor R, Arias A, Ali HR, Cope W, Tiezzi D, Dariush A, Dias Amarante T, Reshef D, Ciriaco N, Martinez-Saez E, Peg V, Ramon Y Cajal S, Cortes J, Vassiliou G, Getz G, Nik-Zainal S, Murtaza M, Friedman N, Markowetz F, Seoane J, Caldas C. The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer. Cell Rep. 2019 May 28;27(9):2690-2708.
  • Gueorguieva I, Cleverly A, Desaiah D, Azaro A, Seoane J, Braña I, Sicart E, Miles C, Lahn MM, Mitchell MI, Rodon J. Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer. Drugs Context. 2016 Dec 2;5:212303. eCollection 2016.
  • Seoane J. The Taming of the TAMs. Trends Cell Biol. 2016 Aug;26(8):562-3.
  • De Mattos-Arruda L, Mayor R, Ng CKY, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramon y Cajal S, Carles J, Rodon J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J*. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nature Communications. 2015; 6:8839. (*corresponding author).
  • Rodon L, Gonzalez-Junca A, Inda MD, Sala-Hojman A, Martinez-Saez E, Seoane J*. Active CREB1 promotes a malignant TGF-β2 autocrine loop in glioblastoma. Cancer Discov. 2014; 4(10):1230-41. (*corresponding author).
  • Serra V, Vivancos A, Puente XS, Felip E, Silberschmidt D, Caratu G, Parra JL, De Mattos-Arruda L, Grueso J, Hernandez-Losa J, Arribas J, Prudkin L, Nuciforo P, Scaltriti M, Seoane J*, Baselga J*. Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation. Cancer Discov. 2013; 3(11):1238-44 (*co-corresponding authors).
  • Eichhorn PJ, Rodon L, Gonzàlez-Juncà A, Dirac A, Gili M, Martínez-Sáez E, Aura C, Barba I, Peg V., Prat A., Cuartas I, Jimenez J, García-Dorado D, Sahuquillo J, Bernards R, Baselga J, Seoane J. USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. Nature Medicine 2012;18(3):429-35. [see News and Views: Aggarwal K and Massagué J. Ubiquitin removal in the TGF- β pathway. Nature Cell Biology. 2012;14(7):656-7].
  • Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, Rodón L, Folch G, Carmona MA, Prieto-Sánchez RM, Barba I, Martínez-Sáez E, Prudkin L, Cuartas I, Raventós C, Martínez-Ricarte F, Poca MA, García-Dorado D, Lahn M, Yingling J, Rodón J, Sahuquillo J, Baselga J, Seoane J. TGF-β receptor inhibitors target the CD44high/Id1high glioma-initiating cell population in human glioblastoma. Cancer Cell. 2010;18(6):655-68 [see Preview: Edwards LA, Fine HA. The Ids have it. Cancer Cell. 2010;18(6):543-5.
All publications

 

  • Hallett R, Bonfill-Teixidor E, Iurlaro R, Arias A, Raman S, Bayliss PE, Egorova O, Neva-Alejo A, McGray AR, Lau E, Bosch A, Beilschmidt M, Maetzel D, Fransson J, Huber-Ruano I, Anido J, Julien JP, Giblin PA, Seoane J Therapeutic targeting of LIF overcomes macrophage mediated immunosuppression of the local tumor microenvironment. Clin Cancer Res . 2022; Online ahead of print.
  • Iurlaro R, Inja Waldhauer, Ester Planas-Rigol , Ester Bonfill-Teixidor, Alexandra Arias, Valeria Nicolini, Anne Freimoser-Grundschober, Isabel Cuartas, Alba Martínez-Moreno, Francisco Martínez-Ricarte  , Esteban Cordero, Marta Cicuendez, Simona Casalino, Xavier Guardia-Reyes, Linda Fahrni , Thomas Pöschinger , Virginie Steinhart, Marine Richard, Stefanie Briner, Joerg Mueller, Franz Osl, Johannes Sam, Sara Colombetti, Marina Bacac, Christian Klein, Estela Pineda, Luis Reyes-Figueroa, Alberto Di Somma, Josep González, Paolo Nuciforo, Joan Carles, Maria Vieito, Josep Tabernero, Pablo Umaña , Seoane, J. A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma. Mol Cancer Ther . 2022;21(10):1499-1509.
  • Pascual,G. Attard,F.-C. Bidard, G. Curigliano,L. De Mattos-Arruda, M. Diehn, A. Italiano J. Lindberg, J.D. MerkerC. Montagut, N. Normanno, K. Pantel, G. Pentheroudakis, S. Popat, J.S. Reis-Filho, J. Tie , Seoane, J, N. Tarazona, T. Yoshino, N.C. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Annals of Oncology , 2022; 33(8):750-768.
  • Borazanci ,A. M. Schram, E. Garralda, I. Brana , M. Vieito Villar , A. Spreafico , M. Oliva, N. J. Lakhani , K. Hoffman, R. M. Hallett , D. Maetzel , F. Hua , J. Hilbert , P. Giblin , J. Anido , A. Kelly , P. J. Vickers , R. Wasserman, Seoane, J , L. L. Siu , D. M. Hyman , D. V. Hoff & J. Tabernero. Phase I, first-in-human study of MSC-1 (AZD0171), a humanized anti-leukemia inhibitory factor monoclonal antibody, for advanced solid tumors. Clinical Trial. ESMO Open . 2022, 7(4):100530.
  • Bonfill-Teixidor E, Iurlaro R, Handl C, Wichmann J, Arias A, Cuartas I, Emmenegger J, Romagnani A, Mangano L, Lorber T, Berrera M, Godfried Sie C, Köchl F, Eckmann J, Feddersen R, Kornacker M, Schnetzler G, Cicuéndez M, Cordero E, Topczewski TE, Ferrés-Pijoan A, Gonzalez J, Martínez-Ricarte F, Muñoz-Couselo E, Tabernero J, Bischoff JR, Pettazzoni P, Seoane J. Activity and resistance of a brain-permeable paradox breaker BRAF inhibitor in melanoma brain metastasis. Cancer Res . 2022, 18;82(14):2552-2564.
  • Soffietti R, Bettegowda C, Mellinghoff IK, Warren KE, Ahluwalia MS, De Groot JF, Galanis E, Gilbert MR, Jaeckle KA, Le Rhun E, Rudà R, Seoane J, Thon N, Umemura Y, Weller M, van den Bent MJ, Vogelbaum MA, Chang SM, Wen PY. Liquid biopsy in gliomas: a RANO review and proposals for clinical applications. Neuro Oncology . 2022, 1;24(6):855-871
  • Seoane J, Escudero L. Cerebrospinal fluid liquid biopsies for medulloblastoma. Nature Reviews Clinical Oncology . 2022;19(2):73-74.
  • Gulley JL, Schlom J, Barcellos-Hoff MH, Wang XJ, Seoane J, Audhuy F, Lan Y, Dussault I, Moustakas A. Dual inhibition of TGF-β and PD-L1 as a novel cancer treatment approach. Molecular Oncology. 2022;16(11):2117-2134.
  • Soffietti R, Bettegowda C, Mellinghoff IK, Warren KE, Ahluwalia MS, De Groot JF, Galanis E, Gilbert MR, Jaeckle KA, Le Rhun E, Rudà R, Seoane J, Thon N, Umemura Y, Weller M, van den Bent MJ, Vogelbaum MA, Chang SM, Wen PY. Liquid biopsy in gliomas: a RANO review and proposals for clinical applications. Neuro Oncol. 2022. (Online ahead of print).
  •  Seoane J, Escudero L. Cerebrospinal fluid liquid biopsies for medulloblastoma. Nature Reviews Clinical Oncology. 2022;19(2):73-74.
  • Gulley JL, Schlom J, Barcellos-Hoff MH, Wang XJ, Seoane J, Audhuy F, Lan Y, Dussault I, Moustakas A. Dual inhibition of TGF-β and PD-L1 as a novel cancer treatment approach. Molecular Oncology.2021. (Online ahead of print).
  • Nieto P, Elosua-Bayes M, Trincado JL, Marchese D, Massoni-Badosa R, Salvany M, Henriques A, Nieto J, Aguilar-Fernández S, Mereu E, Moutinho C, Ruiz S, Lorden P, Chin VT, Kaczorowski D, Chan CL, Gallagher R, Chou A, Planas-Rigol E, Rubio-Perez C, Gut I, Piulats JM, Seoane J, Powell JE, Batlle E, Heyn H. A single-cell tumor immune atlas for precision oncology. Genome Res. 2021; (10):1913-1926.
  • Le Rhun E, Guckenberger M, Smits M, Dummer R, Bachelot T, Sahm F, Galldiks N, de Azambuja E, Berghoff AS, Metellus P, Peters S, Hong Y-K, Winkler F, Schadendorf D, van den Bent M, Seoane J, Stahel R, Minniti G, Wesseling P, Weller M & Preusser M on behalf of the EANO Executive Board and ESMO Guidelines Committee*. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumors. Annals of Oncology. 2021; 32(11): 1332-1347.
  • Escudero L , Martínez-Ricarte F, Seoane J. ctDNA-Based Liquid Biopsy of Cerebrospinal Fluid in Brain Cancer. Cancers. 2021; 13 (9):1989.
  • Rubio-Perez C, Planas-Rigol E, Trincado JL, Bonfill-Teixidor E, Arias A, Marchese D, Moutinho C, Serna G, Pedrosa L, Iurlaro R, Martínez-Ricarte F, Escudero L,  Cordero E, Cicuendez M, Ruiz S, Parra G, Nuciforo P, Gonzalez J, Pineda E, Sahuquillo J, Tabernero J, Heyn H*, Seoane J*. Immune cell profiling of the cerebrospinal fluid enables the characterization of the brain metastasis microenvironment. Nature Communications. 2021. 12(1):1503.
  • Milena Cribiù F, Erra R, Pugni L, Rubio Perez C, Alonso L, Simonetti S, Croci GA, Serna G, Ronchi A, Pietrasanta C, Lunghi G, Fagnani AM, Pinana M, Matter M, Tzankov A, Terracciano L, Anton Pagarolas A, Ferrazzi E, Ferrero S, Iurlaro E, Seoane J*, Nuciforo P*. Severe SARS-CoV-2 placenta infection can impact neonatal outcome in the absence of vertical transmission. (*co-corresponding authors). Journal of Clinical Investigation. 2021. 145427. (Epub ahead of print).
  • Bobillo S, Crespo M, Escudero L, Mayor R, Raheja P, Carpio C, Rubio-Perez C, Tazón-Vega B, Palacio C, Carabia J, Jiménez I, Nieto JC, Montoro J, Martínez-Ricarte F, Castellví J, Simó M, Puigdefàbregas L, Abrisqueta P, Bosch F, Seoane J. Cell free circulating tumor DNA in cerebrospinal fluid detects and monitors central nervous system involvement of B-cell lymphomas. Haematologica. 2021. 106(2):513-521.
  • Escudero L, Martínez-Ricarte F, Seoane J. Cerebrospinal fluid circulating tumour DNA as a liquid biopsy for central nervous system malignancies. Current Opinion Neurology. 2020; 33(6):736-741.
  • Escudero L, Llort A, Arias A, Diaz-Navarro A, Martínez-Ricarte F, Rubio-Perez C, Mayor R, Caratú G, Martínez-Sáez E, Vázquez-Méndez É, Lesende-Rodríguez I, Hladun R, Gros L, Ramón y Cajal S, Poca M, Puente X, Sahuquillo J, Gallego S, Seoane J. Circulating tumour DNA from the cerebrospinal fluid allows the characterisation and monitoring of medulloblastoma. Nature Communications. 2020; 11(1):5376.
  • Ciardiello D, Elez ME, Tabernero J, Seoane J. Clinical development of therapies targeting TGFβ: current knowledge and future perspectives. Annals of Oncology. 2020. 31 (10):1336 – 1349.
  • Seoane J. Immunotherapy Research: today’s science is tomorrow’s medicine. The Innovation Platform. 2020; 1: 122-123.
  • Seoane J, De Mattos-Arruda L, Le Rhun E, Bardelli A, Weller M. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and brain metastases. Annals of Oncology. 2018 Dec 21.
  • Rius Ruiz I, Vicario R, Morancho B, Morales CB, Arenas EJ, Herter S, Freimoser-Grundschober A, Somandin J, Sam J, Ast O, Barriocanal ÁM, Luque A, Escorihuela M, Varela I, Cuartas I, Nuciforo P, Fasani R, Peg V, Rubio I, Cortés J, Serra V, Escriva-de-Romani S, Sperinde J, Chenna A, Huang W, Winslow J, Albanell J, Seoane J, Scaltriti M, Baselga J, Tabernero J, Umana P, Bacac M, Saura C, Klein C, Arribas J. p95HER2-T cell bispecific antibody for breast cancer treatment. Sci Transl Med. 2018 Oct 3;10(461).
  • Puig I, Tenbaum SP, Chicote I, Arques O, Martínez-Quintanilla J, Cuesta-Borrás E, Ramírez L, Gonzalo P, Soto A, Aguilar S, Eguizabal C, Caratu G, Prat A, Argilés G, Landolfi S, Casanovas O, Serra V, Villanueva A, Arroyo A, Terracciano L, Nuciforo P, Seoane J, Recio JA, Vivancos A, Dienstmann R, Tabernero J,  Palmer HG. TET2 Controls Chemoresistant Slow-Cycling Cancer Cells Survival and Tumour Recurrence. Journal of Clinical Investigation. 2018 Aug 31;128(9):3887-3905.
  • Liu Q, Ma L, Jones T, Palomero L, Pujana MA, Martinez-Ruiz H, Ha P, Murnane J, Cuartas I, Seoane J, Baumann M, Linge A, Barcellos-Hoff MH. Subjugation of Tgfβ signaling by human papilloma virus in head and neck squamous cell carcinoma shifts DNA repair from homologous recombination to alternative end joining. Clinical Cancer Research. 2018 Dec 01; 24(23): 6001-6014
  • Seoane J; Capdevila J. The right compound for the right target: tackling RET. Annals of Oncology. 2018 Aug 1; 29(8):1623 -1625.
  • Martínez-Ricarte F., Mayor R., Martínez-Sáez E., Rubio-Pérez C., Pineda E., Cordero E., Cicuéndez M., Poca MA., López-Bigas N., Ramon y Cajal S., Vieito M., Carles J., Tabernero J., Vivancos A., Gallego S., Graus F., Sahuquillo J.,Seoane J. Molecular diagnosis of diffuse gliomas through sequencing of cell-free circulating tumour DNA from cerebrospinal fluid. Clinical Cancer Research. 2018 Jun 15;24(12):2812-2819
  • Capdevila J, Mayor R, Mancuso FF, Iglesias C, Caratù G, Matos I, Zafón C, Hernando J, Petit A, Nuciforo P, Cameselle-Teijeiro JM, Álvarez 4, Recio JA, Tabernero J, Matias-Guiu X, Vivancos A, Seoane J. Early evolutionary divergence between papillary and anaplastic thyroid cancers. Annals of Oncology. 2018 June 1; 29(6): 1454–1460
  • De Mattos-Arruda L, Ng CKY, Piscuoglio S, Gonzalez-Cao M, Lim RS, De Filippo MR, Fusco N, Schultheis AM, Ortiz C, Viteri S, Arias A, Macedo GS, Oliveira M, Gomez P, Teixidó C, Nuciforo P, Peg V, Saura C, Ramon Y Cajal S, Casas FT, Weigelt B, Cortes J, Seoane J, Reis-Filho JS. Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. Oncotarget. 2018 Apr 17; 9(29):20617-20630
  • Yates L. R., Seoane J., Le Tourneau C., Siu L.L., Marais R., Michiels S., Soria J.C., Campbell P., Normanno N., Scarpa A., Reis-Filho J., Rodon J., Swanton C., Andre F. The European Society of Medical Oncology (ESMO) Precision Medicine Glossary. Annals of Oncology. 2018; 29(1):30-35
  • Seoane J. Cancer Division hierarchy leads to cell heterogeneity. Nature. 2017; 549(7671):164-166.
  • Huber-Ruano I, Raventos C, Cuartas I, Sánchez-Jaro C, Wosikowski K, Janicot M, Seoane J. An antisense oligonucleotide targeting TGF-β2 inhibits lung metastasis and induces CD86 expression in tumor-associated macrophages. Annals of Oncology. 2017; 28(9):2278-2285.
  • Gonzalez-Cao M, Berrocal A, Puig S, Karachaliou N, De Matos-Arruda L, Seoane J, Escors D, Alvarez C, Vaque J P, Prat A, Wellbrock C, Arozarena I, Marquez-Rodas I, Espinosa E, Molina M A, Puertolas T, Juan-Otero M, Malagrida R, Jantus-Lewintre E, Soriano V, Arance A, ManzanoJ L, Lorigan P, Gajewski T F, Rosell R, Martin-Algarra S; On behalf of the Spanish Melanoma Group (GEM) Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). Annals of Translational Medicine 2017; 5(19):390.
  • Seoane J., Gomis RR. TGFβ Family Signaling in Tumor Suppression and Cancer Progression. Cold Spring Harbor Perspectives in Biology. 2017; 9 (12)
  • Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature Reviews Cancer.  2017; 17(4):254-268.
  • Gueorguieva I, Cleverly A, Desaiah D, Azaro A, Seoane J, Braña I, Sicart E, Miles C, Lahn MM, Mitchell MI, Rodon J. Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer.  Drugs Context. 2016 Dec 2;5:212303. eCollection 2016.
  • Seoane J. The Taming of the TAMs. Trends Cell Biol. 2016 Aug;26(8):562-3.
  • Gomis R, Seoane J. TGFβ Family Signaling in Tumor Suppression and Cancer Progression. Cold Harbor 2016. In press 2016
  • Byrne A, Alferez D, Amant F, Annibali D, Arribas J, Biankin A, Bruna A, Budinská E, Caldas C, Chang D, Clarke R, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek M, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer H, Peeper D, Pelicci PG, Piris A, Roman-Roman S, Rueda O, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L. Interrogating open issues in oncology and cancer precision medicine using Patient-Derived Xenograft models. Nature Review Cancer. In Press 2016
  • Gueorguieva I, Cleverly A, Desaiah D, Azaro A, Seoane J, Braña I, et al. Drugs in Context 2016; 5:201303. “Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer”, Drugs in Context, 2016; 5: 201303. DOI: 10.7573/dic.212303
  • Seoane J. The Taming of the TAMs. Trends in Cell Biology. Aug;26(8):562-3. doi: 10.1016/j.tcb.2016.06.007. Epub 2016 Jul 6.
  • De Mattos-Arruda L, Mayor R, Ng CKY, Weigelt B, Martínez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J, Guerini-Rocco E, Martínez-Sáez E, Lois S, Marín O, de la Cruz X, Piscuoglio S, Towers R, Vivancos A, Peg V, Ramon y Cajal S, Carles J, Rodon J, González-Cao M, Tabernero J, Felip E, Sahuquillo J, Berger MF, Cortes J, Reis-Filho JS, Seoane J*. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nature Communications. 2015; 6:8839. (*corresponding author).
  • De Mattos-Arruda L, Bottai G, Nuciforo PG, Di Tommaso L, Giovannetti E, Peg V, Losurdo A, Pérez-Garcia J, Masci G, Corsi F, Cortés J, Seoane J, Calin GA, Santarpia L. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget. 2015;6(35):37269-80.
  • Brastianos PK, Carter SL, Santagata S, Cahill DP, Taylor-Weiner A, Jones RT, Van Allen EM, Lawrence MS, Horowitz PM, Cibulskis K, Ligon KL, Tabernero J, Seoane J, Martinez-Saez E, Curry WT, Dunn IF, Paek SH, Park SH, McKenna A, Chevalier A, Rosenberg M, Barker FG 2nd, Gill CM, Van Hummelen P, Thorner AR, Johnson BE, Hoang MP, Choueiri TK, Signoretti S, Sougnez C, Rabin MS, Lin NU, Winer EP, Stemmer-Rachamimov A, Meyerson M, Garraway L, Gabriel S, Lander ES, Beroukhim R, Batchelor TT, Baselga J, Louis DN, Getz G, Hahn WC. Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. Cancer Discov. 2015;5(11):1164-77
  • Iyengar PV, Jaynes P, Rodon L, Lama D, Law KP, Lim YP, Verma C, Seoane J, Eichhorn PJ. USP15 regulates SMURF2 kinetics through C-lobe mediated deubiquitination. Sci Rep. 2015;5:14733.
  • Ulloa F, Gonzàlez-Juncà A, Meffre D, Barrecheguren PJ, Martínez-Mármol R, Pazos I, Olivé N, Cotrufo T, Seoane J, Soriano E. Blockade of the SNARE Protein Syntaxin 1 Inhibits Glioblastoma Tumor Growth. PLoS One. 2015;10(3):e0119707.
  • Rodon J, Carducci MA, Sepulveda-Sanchez JM, Azaro A, Calvo E, Seoane J, Brana I, Sicart E, Gueorguieva I, Cleverly AL, Sokalingum Pillay N, Desaiah D, Estrem ST, Paz-Ares L, Holdoff M, Blakeley J, Lahn MM, Baselga J. First-in-Human Dose Study of the Novel Transforming Growth Factor-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Patients with Advanced Cancer and Glioma. Clin Cancer Res. 2015;21(3):553-60.
  • Rodon J, Carducci M, Sepulveda-Sánchez JM, Azaro A, Calvo E, Seoane J, Braña I, Sicart E, Gueorguieva I, Cleverly A, Pillay NS, Desaiah D, Estrem ST, Paz-Ares L, Holdhoff M, Blakeley J, Lahn MM, Baselga J. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer. Invest New Drugs. 2015;33(2):357-70.
  • Seoane J*, De Mattos-Arruda L. Escaping out of the brain. Cancer Discov. 2014;4(11):1259-61. (*corresponding author)
  • Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, Roman-Roman S, Seoane J, Trusolino L, Villanueva A. Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. Cancer Discov. 2014;4(9):998-1013.
  • Henderson D, Ogilvie LA, Hoyle N, Keilholz U, Lange B, Lehrach H on behalf of the OncoTrack Consortium. Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack. Biotechnol J. 2014;9(9):1104-14.
  • Rodon L, Gonzalez-Junca A, Inda MD, Sala-Hojman A, Martinez-Saez E, Seoane J*. Active CREB1 promotes a malignant TGF-β2 autocrine loop in glioblastoma. Cancer Discov. 2014;4(10):1230-41. (*corresponding author)
  • Annibali D, Whitfield JR, Favuzzi E, Jauset T, Serrano E, Cuartas I, Redondo-Campos S, Folch G, Gonzalez-Juncà A, Sodir NM, Masso-Vallés D, Beaulieu ME, Swigart LB, Mc Gee MM, Somma MP, Nasi S, Seoane J, Evan GI, Soucek L. Myc inhibition is effective against glioma and reveals a role for Myc in mitosis. Nature Communications. 2014;5:4632.
  • De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CK, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Tabernero J, Berger MF, Seoane J, Reis-Filho JS. Capturing Intra-Tumor Genetic Heterogeneity by De Novo Mutation Profiling of Circulating Cell-Free Tumor DNA: A Proof-of-Principle. Ann Oncol. 2014;25(9):1729-35.
  • Martino-Echarri E, Fernández-Rodríguez R, Bech-Serra JJ, Plaza-Calonge MC, Vidal N, Casal C, Colomé N, Seoane J*, Canals F, Rodríguez-Manzaneque JC. Relevance of IGFBP2 proteolysis in glioma and contribution of the extracellular protease ADAMTS1. Oncotarget. 2014;5(12):4295-304. (*corresponding author)
  • Seoane J. Gremlins Sabotage the Mechanisms of Cancer Stem Cell Differentiation. Cancer Cell. 2014;25(6):716-7.
  • Seoane J*, De Mattos-Arruda L. Brain metastasis: new opportunities to tackle therapeutic resistance. Review Article, Mol Oncol. 2014;8(6):1120-31. (*corresponding author).
  • Seoane J*, De Mattos-Arruda L. The challenge of intratumour heterogeneity in precision medicine. J Intern Med. 2014;276(1):41-51. (*corresponding author)
  • Inda MD, Bonavia R, Seoane J*. Glioblastoma multiforme: a look inside its heterogeneous nature. Cancers (Basel). 2014;6(1):226-39. (*co-corresponding author).
  • Cortés J, Calvo E, Vivancos A, Perez-Garcia J, Recio JA, Seoane J. New approach to cancer therapy based on a molecularly defined cancer classification. CA-Cancer J Clin. 2014;64(1):70-4.
  • De Mattos-Arruda L, Bidard FC, Won HH, Cortes J, Ng CK, Peg V, Nuciforo P, Jungbluth AA, Weigelt B, Berger MF, Seoane J*, Reis-Filho JS. Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing. Mol Oncol. 2014;8(1):150-8 (*co-corresponding authors).
  • Serra V, Vivancos A, Puente XS, Felip E, Silberschmidt D, Caratu G, Parra JL, De Mattos-Arruda L, Grueso J, Hernandez-Losa J, Arribas J, Prudkin L, Nuciforo P, Scaltriti M, Seoane J*, Baselga J*. Clinical response to a lapatinib-based therapy of a Li-Fraumeni Syndrome patient with a novel HER2-V659E mutation. Cancer Discov. 2013;3(11):1238-44 (*co-corresponding authors).
  • De Mattos-Arruda L, Cortes J, Santarpia L, Vivancos A, Tabernero J, Reis-Filho JS, Seoane J. Circulating Tumor Cells and Cell-Free DNA as Tools for Managing Breast Cancer. Nature Reviews. Clinical Oncology. 2013;10(7):377-89.
  • De Mattos-Arruda L, Tabernero J, Seoane J, Cortes J. Circulating tumour cells in early breast cancer. Lancet Oncol. 2012;13(9):e370.
  • Ros-Blanco L, Anido J, Bosser R, Este J, Clotet B, Kosoy A, Ruiz-Avila L, Teixido J, Seoane J*, Borrell JI. NonCyclam Tetraamines inhibit CXC Chemokine Receptor Type 4 and target Glioma-Initiating Cells. J Med Chem. 2012;55(17):7560-70 (*co-corresponding author).
  • Eichhorn PJ, Rodon L, Gonzàlez-Juncà A, Dirac A, Gili M, Martínez-Sáez E, Aura C, Barba I, Peg V., Prat A., Cuartas I, Jimenez J, García-Dorado D, Sahuquillo J, Bernards R, Baselga J, Seoane J. USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. Nature Medicine 2012;18(3):429-35. [see News and Views: Aggarwal K and Massagué J. Ubiquitin removal in the TGF- β pathway. Nature Cell Biology. 2012;14(7):656-7].
  • Anido J, Sáez-Borderías A, Gonzàlez-Juncà A, Rodón L, Folch G, Carmona MA, Prieto-Sánchez RM, Barba I, Martínez-Sáez E, Prudkin L, Cuartas I, Raventós C, Martínez-Ricarte F, Poca MA, García-Dorado D, Lahn M, Yingling J, Rodón J, Sahuquillo J, Baselga J, Seoane J. TGF-β receptor inhibitors target the CD44high/Id1high glioma-initiating cell population in human glioblastoma. Cancer Cell. 2010;18(6):655-68 [see Preview: Edwards LA, Fine HA. The Ids have it. Cancer Cell. 2010;18(6):543-5.
  • Seoane J. NO Signals from the Cancer Stem Cell Niche. Cell Stem Cell. 2010;6(2):97-8.
  • Seoane J. TGF-β and cancer initiating cells. Cell Cycle. 2009;8(23):3787-8.
  • Santamaria-Martínez A, Barquinero J, Barbosa-Desongles A, Hurtado A, Pinós T, Seoane J, Poupon MF, Morote J, Reventós J, Munell F. Identification of multipotent mesenchymal stromal cells in the reactive stroma of a prostate cancer xenograft by side population analysis. Exp Cell Res. 2009 ;315(17):3004-13.
  • Peñuelas S, Anido J, Prieto-Sánchez RM, Folch G, Barba I, Cuartas I, García-Dorado D, Poca MA, Sahuquillo J, Baselga J, Seoane J. TGF-β increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell. 2009;15(4):315-27 [see Preview: Fine HA. Glioma stem cells: not all created equal. Cancer Cell. 2009;15(4):247-9].
  • Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3- kinase inhibitor NVP-BEZ235. Cancer Res. 2008;68(22):9221-30.
  • Seoane J. The TGF-β pathway as a therapeutic target in cancer. Clin Transl Oncol. 2008;10(1):14-19.
  • Baselga J, Rothenberg ML, Tabernero J, Seoane J, Daly T, Cleverly A, Berry B, Rhoades SK, Ray CA, Fill J, Farrington DL, Anne L, Yingling JM, Lahn M, Arteaga C, Carducci M. TGF-β signaling related markers in cancer patients with bone metastasis. Biomarkers. 2008;13(2):217-36.
  • Seoane J. TGF-β signaling in homeostasis and cancer. In: Jakowlew SB (ed.) Cancer Drug Discovery and Development: Transforming Growth Factor-Beta in Cancer Therapy, Vol. 1: Basic and Clinical Biology . 1st ed. Totowa, NJ: Humana Press; 2008. pp 23-35.
  • Bruna A, Darken RS, Rojo F, Ocaña A, Peñuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, Seoane J. High TGF-β-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell. 2007;11,147-160 [see Preview: Kesari S, Jackson-Grusby L, Stiles CD. “Smad”eningly erratic: target gene methylation determines whether TGFbeta promotes or suppresses malignant glioma. Dev Cell. 2007;12(3):324-5.].
  • Gomis RR, Alarcón C, He W, Wang Q, Seoane J, Lash A and Massagué J. A FoxO-Smad synexpression group in human keratinocytes. P Natl Acad Sci USA. 2006;103(34):12747-52.
  • Seoane J. Escaping from the TGF-β anti-proliferative control. Carcinogenesis. 2006;27(11):2148-56.
  • Massagué J, Seoane J, Wotton D. Smad Transcription Factors. Gene Dev. 2005;19,2783-2810.
  • Seoane J, Le H-V, Shen L, Anderson SA, Massagué J. Integration of Smad and Forkhead Pathways in the Control of Neuroepithelial and Glioblastoma Cell Proliferation. Cell. 2004;117,211-223 (Cover) [see Preview: Arden KC. FoxO: Linking new signaling pathways. Mol Cell. 2004;14(4):416-8].
  • Seoane J. p21(WAF1/CIP1) at the Switch Between the Anti-Oncogenic and Oncogenic Faces of TGF-β. Cancer Biol Ther. 2004;3(2):226-7.
  • Calonge J, Seoane J, Massagué J. Opposite Smad and chicken ovalbumin upstream promoter transcription factor inputs in the regulation of the collagen VII gene promoter by transforming growth factor-β. J Biol Chem. 2004;279(22):23759-65.
  • Seoane J, Le H-V, Massagué J. Myc suppression of p21Cip1 Cdk inhibitor determines the outcome of the p53 response to DNA damage. Nature. 2002;419(6908):729-34 [see Preview: Vousden KH. Switching from life to death: the Miz-ing link between Myc and p53. Cancer Cell. 2002;2(5):351-2].
  • Wu J-W, Hu M, Chai J, Seoane J, Huse M, Li C, Kyin S, Fairman R, Muir TW, Massague J, Shi Y. Crystal structure of a phosphorylated Smad2: Recognition of phosphoserine by the MH2 domain and insights on Smad function in TGF-β signaling. Mol Cell. 2001;8(6):1277-89.
  • Seoane J, Pouponnot C, Staller P, Schader M, Eilers M, Massagué J. TGF-β influences Myc, Miz-1 and Smad to control the CDK inhibitor p15Ink4b. Nature Cell Biology. 2001;3(4):400-8.
  • Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, Moroy T, Bartek J, Massagué J, Hanel F, Eilers M. Repression of p15Ink4b expression by Myc through association with Miz-1. Nature Cell Biology. 2001;3,392-399.
  • Hata A, Seoane J, Lagna G, Montalvo E, Hemmati-Brivanlou A, Massagué J.  OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways. Cell. 2000;100(2):229-40.
  • De la Iglesia N, Mukhtar M, Seoane J, Guinovart JJ, Agius L. The role of the regulatory protein of glucokinase in the glucose sensory mechanism of the hepatocyte. J Biol Chem. 2000;275(14):10597-603.
  • Warner BJ, Blain SW, Seoane J, Massagué J. Myc downregulation by transforming growth factor beta required for activation of the p15 Ink4b G1 arrest pathway. Mol Cell Biol. 1999;19(9):5913-22.
  • Seoane J, Barberà A, Telemaque-Potts S, Newgard SB, Guinovart JJ. Glucokinase overexpression restores glucose utilization and storage in cultured hepatocytes from male zucker diabetic fatty rats. J Biol Chem. 1999;274(45):31833-8.
  • Seoane J, Trinh K, O’Doherty RM, Gómez-Foix AM, Lange AJ, Newgard CB, Guinovart JJ. Metabolic impact of adenovirus-mediated overexpression of the glucose 6-phosphatase catalytic subunit in hepatocytes. J Biol Chem. 1997;272(43):26972-7.
  • Guinovart JJ, Gómez-Foix AM, Seoane J, Fernández-Novell JM, Bellido D, Vilaró S. Bridging the gap between glucose phosphorylation and glycogen synthesis in the liver. Biochem Soc T. 1997;25(1):157-60.
  • Seoane J, Gómez-Foix AM, O´Doherty RM, Gómez-Ara C, Newgard CB, Guinovart JJ. Glucose 6-phosphate produced by glucokinase, but not hexokinase I, promotes the activation of hepatic glycogen synthase. J Biol Chem. 1996;271(39):23756-60.
  • O’Doherty RM, Lehman DL, Seoane J, Gómez-Foix AM, Guinovart JJ, Newgard CB. Differential metabolic effects of adenovirus-mediated glucokinase and hexokinase I overexpression in rat primary hepatocytes. J Biol Chem. 1996;271(34):20524-30.
Privacy Preferences
When you visit our website, it may store information through your browser from specific services, usually in form of cookies. Here you can change your privacy preferences. Please note that blocking some types of cookies may impact your experience on our website and the services we offer.
Privacy Policy
You have read and agreed to our privacy policy
Required